← All trials
NCT04952727
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 26, 2021
- Primary completion
- Nov 26, 2021
- Completion date
- May 26, 2022
- First posted
- Jul 7, 2021
- Last posted
- Sep 29, 2021
- Enrollment
- 300
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Government of ChinaLead sponsor
- Government of ChinaOverall official - principal investigator
- Tianjin Cansino Biotechnology IncCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.